邓涛;年悬悬;张家友;黄仕和;杨晓明;

• 1:武汉生物制品研究所有限责任公司
• 2:国家联合疫苗工程技术研究中心
• 3:中国生物技术股份有限公司

摘要(Abstract)：

新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)是由重症急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染引起的呼吸道传染病。COVID-19在全球范围的大流行造成了严重的公共卫生危机,已成为导致死亡的主要原因之一。为减轻COVID-19对公共健康和社会经济的影响,全球疫苗研发机构均在积极开发疫苗,目前上市的COVID-19疫苗包括灭活疫苗、病毒载体疫苗、mRNA疫苗和重组蛋白疫苗等多种类型。传统经典的灭活疫苗由于其生产工艺成熟、安全性良好、免疫原性稳定、可及性强,受到众多疫苗企业的青睐。目前已有多款COVID-19灭活疫苗获得紧急使用或批准附条件上市。本文就COVID-19灭活疫苗研发的毒种与细胞基质选择、生产工艺、临床前研究、对突变株的保护作用作一综述,并着重探讨COVID-19灭活疫苗的临床研究进展及其面临的挑战。

关键词(KeyWords)： 新型冠状病毒肺炎;重症急性呼吸综合征冠状病毒2;灭活疫苗;临床试验;安全性;有效性

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划“2019-nCoV灭活疫苗”项目（2020YFC0842100）

作者(Authors): 邓涛;年悬悬;张家友;黄仕和;杨晓明;

DOI: 10.13200/j.cnki.cjb.003388

参考文献(References)：

• [1]GRAHAM R L,BARIC R S.Recombination,reservoirs,and the modular spike:mechanisms of coronavirus cross-species transmission[J].J Virol,2010,84(7):3134-3146.
• [2]ZHOU P,YANG X L,WANG X G,et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,579(7798):270-273.
• [3]WHO.Coronavirus disease(COVID-19)pandemic[EB/OL].(2020-05-10)[2021-05-30].https：//www.who.int/zh/emer gencies/diseases/novel-coronavirus-2019.
• [4]WHO.WHO Coronavirus(COVID-19) Dashboard[EB/OL].(2021-05-11)[2021-05-30].https：//covid19.who.int/table.
• [5]WHO.Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL].(2021-05-11)[2021-05-30].https：//www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
• [6]Coronavirus today.COVID-19 VACCINES (2021)[EB/OL].(2021-05-11)[2021-05-30].https：//www.coronavirustoday.com/covid-19-vaccines.
• [7]ZHAO J,ZHAO S,OU J,et al.COVID-19:coronavirus vaccine development updates[J].Front Immunol,2020,11:1-19.
• [8]WEISS S R.Forty years with coronaviruses[J].J Exp Med,2020,217(5):e20200537.
• [9]LU R,ZHAO X,LI J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
• [10]LI Q,GUAN X,WU P,et al.Early transmission dynamics in wuhan,china,of novel coronavirus-infected pneumonia[J].NEngl J Med,2020,382(13):1199-1207.
• [11]BHAT E A,KHAN J,SAJJAD N,et al.SARS-Co V-2:Insight in genome structure,pathogenesis and viral receptor binding analysis-An updated review[J].Int Immunopharmacol,2021,95:1-9.
• [12]HATMAL M M,ALSHAER W,AL-HATAMLEH M,et al.Comprehensive structural and molecular comparison of spike proteins of SARS-Co V-2,SARS-Co V and MERS-Co V,and their interactions with ACE2[J].Cells,2020,9(12):2638.
• [13]CHEN N,ZHOU M,DONG X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507-513.
• [14]WANG H,ZHANG Y,HUANG B,et al.Development of an inactivated vaccine candidate,BBIBP-Cor V,with potent protection against SARS-Co V-2[J].Cell,2020,182(3):713-721.
• [15]YAO Y F,WANG Z J,JIANG R D,et al.Protective efficacy of inactivated vaccine against SARS-Co V-2 infection in mice and non-human primates[J].Virol Sin,2021:1-11[preprint].
• [16]WANG Z J,ZHANG H J,LU J,et al.Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models[J].Emerg Microbes Infect,2020,9(1):2606-2618.
• [17]XIA S,DUAN K,ZHANG Y,et al.Effect of an inactivated vaccine against SARS-Co V-2 on safety and immunogenicity outcomes:Interim analysis of 2 randomized clinical trials[J].JAMA,2020,324(10):951-960.
• [18]GAO Q,BAO L,MAO H,et al.Development of an inactivated vaccine candidate for SARS-Co V-2[J].Science,2020,369(6499):77-81.
• [19]ELLA R,VADREVU K M,JOGDAND H,et al.Safety and immunogenicity of an inactivated SARS-Co V-2 vaccine,BBV-152:a double-blind,randomised,phase 1 trial[J].Lancet Infect Dis,2021,21(5):637-646.
• [20]SARKALE P,PATIL S,YADAV P D,et al.First isolation of SARS-Co V-2 from clinical samples in India[J].Indian J Med Res,2020,151(2&3):244-250.
• [21]WANG L,FANG X,BONENFANT G,et al.Susceptibility to SARS-Co V-2 of cell lines and substrates commonly used to diagnose and isolate influenza and other viruses[J].Emerg Infect Dis,2021,27(5):1380-1392.
• [22]HUANG Z,JIANG Q,WANG Y,et al.SARS-Co V-2 inactivated vaccine(Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats[J].Food Chem Toxicol,2021,152:1-5.
• [23]GALLO-RAM魱REZ L E,NIKOLAY A,GENZEL Y,et al.Bioreactor concepts for cell culture-based viral vaccine production[J].Expert Rev Vaccin,2015,14(9):1181-1195.
• [24]RAGAN I K,HARTSON L M,DUTT T S,et al.A whole virion vaccine for COVID-19 produced via a novel inactivation method and preliminary demonstration of efficacy in an animal challenge model[J].Vaccines(Basel),2021,9(4):1-5.
• [25]ABD-ELGHAFFAR A,ALI A E,BOSEILA A,et al.Inactivation of rabies virus by hydrogen peroxide[J].Vaccine,2016,34(6):798-802.
• [26]KUMAR V,LOCKERBIE O,KEIL S D,et al.Riboflavin and UV-light based pathogen reduction:extent and consequence of DNA damage at the molecular level[J].Photochem Photobiol,2004,80:15-21.
• [27]KARAKUS G S,TASTAN C,KANCAGI D D,et al.Preclinical efficacy and safety analysis of gamma-irradiated inacti-vated SARS-Co V-2 vaccine candidates[J].Sci Rep,2021,11(1):1-19.
• [28]THANH L T,ANDREADAKIS Z,KUMAR A,et al.The COVID-19 vaccine development landscape[J].Nat Rev Drug Discov,2020,19(5):305-306.
• [29]YADAV P D,ELLA R,KUMAR S,et al.Immunogenicity and protective efficacy of inactivated SARS-Co V-2 vaccine candidate,BBV152 in rhesus macaques[J].Nat Commun,2021,12(1):1-12.
• [30]YU P,QI F,XU Y,et al.Age-related rhesus macaque models of COVID-19[J].Animal Model Exp Med,2020,3(1):93-97.
• [31]CARLOS W G,CRUZ C S D,CAO B,et al.COVID-19:How do we stay safe[J].Am J Respir Crit Care Med,2020,202(5):15-16.
• [32]WAN Y,SHANG J,SUN S,et al.Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J].J Virol,2020,94(5):e02015-02019.
• [33]TAKADA A,WATANABE S,OKAZAKI K,et al.Infectivityenhancing antibodies to Ebola virus glycoprotein[J].J Virol,2001,75(5):2324-2330.
• [34]TAKADA A,FELDMANN H,KSIAZEK T G,et al.Antibodydependent enhancement of Ebola virus infection[J].J Virol,2003,77(13):7539-7544.
• [35]TETRO J A.Is COVID-19 receiving ADE from other coronaviruses[J].Microbes Infect,2020,22(2):72-73.
• [36]WANG S F,TSENG S P,YEN C H et al.Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins[J].Biochem Biophys Res Commun,2014,45(2):208-214.
• [37]ZHANG Y N,LI X D,ZHANG Z R,et al.A mouse model for SARS-Co V-2 infection by exogenous delivery of h ACE2 using alphavirus replicon particles[J].Cell Res,2020,30 (11):1046-1048.
• [38]CORBETT K S,FLYNN B,FOULDS K E,et al.Evaluation of the m RNA-1273 vaccine against SARS-Co V-2 in nonhuman primates[J].N Engl J Med,2020,383(16):1544-1555.
• [39]VOGEL A B,KANEVSKY I,CHE Y,et al.Immunogenic BNT-162b vaccines protect rhesus macaques from SARS-Co V-2[J].Nature,2020,592(7853):283-289.
• [40]TIAN J H,PATEL N,HAUPT R,et al.SARS-Co V-2 spike glycoprotein vaccine candidate NVX-Co V2373 immunogenicity in baboons and protection in mice[J].Nat Commun,2021,12(1):1-14.
• [41]VAN DOREMALEN N,LAMBE T,SPENCER A,et al.Ch A-d Ox1 n Co V-19 vaccine prevents SARS-Co V-2 pneumonia in rhesus macaques[J].Nature,2020,586(7830):578-582.
• [42]MERCADO N B,ZAHN R,WEGMANN F,et al.Single-shot Ad26 vaccine protects against SARS-Co V-2 in rhesus macaques[J].Nature,2020,586(7830):583-588.
• [43]CHEN H,XIE Z,LONG R,et al.A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-Co V-2 infection[J].bioRxiv,2020:1-31[preprint].
• [44]北京生物制品研究所有限责任公司.新型冠状病毒（2019-Co V）灭活疫苗（Vero细胞）Ⅰ/Ⅱ期临床试验[EB/OL].(2020-04-29)[2021-05-12].http：//www.chictr.org.cn/showproj.asp x?proj=53003.
• [45]中国生物.国药集团中国生物新冠灭活疫苗获批附条件上市.[EB/OL].(2020-12-31)[2021-05-12].https：//www.cnbg.com.cn/content/details_12_5965.html.
• [46]XIA S,ZHANG Y,WANG Y,et al.Safety and immunoge nicity of an inactivated SARS-Co V-2 vaccine,BBIBP-Cor V:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J].Lancet Infect Dis,2021,21(1):39-51.
• [47]NAWAL A K,ZHANG Y,XIA S,et al.Effect of 2 inactivated SARS-Co V-2 vaccines on symptomatic COVID-19 infection in adults:A randomized clinical trial[J].JAMA,2021.https：//doi.org/10.1001/jama.2021.8565.
• [48]科兴.WHO免疫战略咨询专家组（SAGE）公布SINOVAC科兴新冠疫苗评估报告[EB/OL].(2021-05-01)[2021-05-12].http：//www.sinovac.com/news/shownews.php?id=1216.
• [49]ZHANG Y,ZENG G,PAN H,et al.Safety,tolerability,and immunogenicity of an inactivated SARS-Co V-2 vaccine in hea lthy adults aged 18-59 years:a randomised,double-blind,placebo-controlled,phase 1/2 clinical trial[J].Lancet Infect Dis,2021,21(2):181-192.
• [50]PALACIOS R,PATINO EG,DE OLIVEIRA PIORELLI R,et al.Double-blind,randomized,placebo-controlled phase III cli nical trial to evaluate the efficacy and safety of treating heal thcare professionals with the adsorbed COVID-19(inactivated)vaccine manufactured by Sinovac-PROFISCOV:A structured summary of a study protocol for a randomised controlled trial[J].Trials,2020,21(1):1-3.
• [51]Chinese Academy of Medical Sciences.Safety and immunogen icity study of an inactivated SARS-Co V-2 vaccine for preventing against COVID-19[EB/OL].(202006-02-xx)[2021-05-12].https：//clinicaltrials.gov/ct2/show/NCT04412538.
• [52]CHE Y,LIU X,PU Y,et al.Randomized,double-blinded and placebo-controlled phase II trial of an inactivated SARS-Co V-2 vaccine in healthy adults[J].Clin Infect Dis,2020:1-7[preprint].
• [53]PU J,YU Q,YIN Z,et al.The safety and immunogenicity of an inactivated SARS-Co V-2 vaccine in Chinese adults aged 18-59 years:A phase I randomized,double-blinded,controlled trial[J].Vaccine,2021,39(20):2746-2754.
• [54]PAN H X,LIU J K,HUANG B Y,et al.Immunogenicity and safety of a SARS-Co V-2 inactivated vaccine in healthy adults:randomized,double-blind,and placebo-controlled phase 1 and phase 2 clinical trials[J].Chin Med J(Engl).2021,134(11):1289-1298.
• [55]ELLA R,MOHAN K,JOGDAND H,et al.Safety and immu nogenicity trial of an inactivated SARS-Co V-2 vaccine BBV152[J].med Rxiv,2020:1-21[preprint].
• [56]ELLA R,REDDY S,JOGDAND H,et al.Safety and immuno genicity of an inactivated SARS-Co V-2 vaccine,BBV152:inte rim results from a double-blind,randomised,multicentre,pha se 2 trial,and 3-month follow-up of a double-blind,randomi sed phase 1 trial[J].Lancet Infect Dis,2021,21 (5):637-646.
• [57]VOLZ E,HILL V,MCCRONE J T,et al.Evaluating the effe cts of SARS-Co V-2 spike mutation D614G on transmissibility and pathogenicity[J].Cell.2021,184(1):64-75.
• [58]CHEN F,LI B,HAO P,et al.A case of new variant COVID-19 first emerging in south Africa detected in airplane pilotGuangdong province,China,January 6,2021[J].Chin CDCWkly,2021,3(2):28-29.
• [59]BIAN L,GAO F,ZHANG J,et al.Effects of SARS-Co V-2variants on vaccine efficacy and response strategies[J].Expert Rev Vaccines,2021:1-9[preprint].
• [60]HUANG B,DAI L,WANG H,et al.Neutralization of SARS-Co V-2 VOC 501Y.V2 by human antisera elicited by both ina ctivated BBIBP-Cor V and recombinant dimeric RBD ZF2001vaccines[J].bio Rxiv,2021:1-12[preprint].
• [61]CHEN Y,SHEN H,HUANG R,et al.Serum neutralising acti vity against SARS-Co V-2 variants elicited by Corona Vac[J].Lancet Infect Dis,2021.https：//doi.org/10.1016/S1473-3099(21)00287-5.
• [62]中国生物.全球最大COVID-19疫苗车间封顶[EB/OL].(2021-05-06)[2021-05-12].https：//mp.weixin.qq.com/s/z QW6qzk Vxmbtnt PHN-al LA.
• [63]WANG D,HU B,HU C,et al.Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J].JAMA,2020,323(11):1061-1069.
• [64]WANG X L,GUO X H,XIN Q Q,et al.Neutralizing antibodies responses to SARS-Co V-2 in COVID-19 inpatients and convalescent patients[J].Clin Infect Dis,2020,71 (10):2688-2694.
• [65]DARNELL M,SUBBARAO K,FEINSTONE S M,et al.Inactivation of the coronavirus that induces severe acute respiratory syndrome,SARS-Co V[J].J Virol Methods,2004,121(1):85-91.
• [66]SMATTI M,AL T A,YASSINE H.Viral-induced enhanced disease illness[J].Front Microbiol,2018,9(2991):1-19.